|1.||Kim, Sung-Hoon: 15 articles (08/2012 - 08/2005)|
|2.||Lü, Junxuan: 9 articles (08/2011 - 09/2008)|
|3.||Jeong, Soo-Jin: 7 articles (08/2012 - 01/2010)|
|4.||Lee, Hyo-Jeong: 7 articles (08/2012 - 09/2008)|
|5.||Zhang, Jinhui: 7 articles (02/2011 - 09/2008)|
|6.||Lee, Hyo-Jung: 6 articles (08/2012 - 01/2010)|
|7.||Kitazato, Kaio: 5 articles (10/2014 - 01/2011)|
|8.||Hu, Hongbo: 5 articles (02/2014 - 09/2008)|
|9.||Lee, Eun-Ok: 5 articles (03/2012 - 08/2005)|
|10.||Liu, Ge: 4 articles (10/2014 - 02/2011)|
|1.||Neoplasm Metastasis (Metastasis)
06/01/2011 - "PGG treatment also decreased the incidence of lung metastasis. "
06/01/2011 - "Orally administered PGG can inhibit TNBCa growth and metastasis, probably through anti-angiogenesis, antiproliferation and apoptosis induction. "
09/10/2014 - "Therefore, PGG may be able to be used as a potential new therapeutic drug for prostate cancer bone metastasis."
09/10/2014 - "This study utilized proteomics to analyze the effects of PGG in EGF-induced prostate cancer bone metastasis. "
11/28/2015 - "The correlation of CCND1 G870A polymorphism with tumor response in patients was assessed. Compared with patients with AA genotype, the patients with GG genotype and AA genotype showed lower sensitivity to radio-therapy treatment (adjusted ORGA=2.69, 95% CI 1.28-5.67 and adjusted ORGG=3.28, 95% CI 1.47-7.29, respectively), an increase in risks of recurrence/metastasis (adjusted ORGA=2.52, 95% CI 1.12-5.63 and adjusted ORGG=3.95, 95% CI 1.68-9.26, respectively), and shorter recurrence/metastasis-free survival (PGA=0.010 and PGG=0.045). G870A polymorphism is a frequent variation that could be used for evaluate the radio-sensitivity and prognosis for patients with HR-HPV related cervical cancer. "
|2.||Kidney Neoplasms (Kidney Cancer)
03/01/2012 - "In the present study, we demonstrate that 1,2,3,4,6-penta-O-galloyl-β-d-glucose (PGG) has protective effects against cisplatin-induced cytotoxicity and apoptosis in normal human primary renal epithelial cells (HRCs) while showing synergistic effect against cisplatin-induced cell death in human Caki-2 renal cancer cells. "
03/01/2012 - "Taken together, our findings suggest the dual effects of PGG as a protective supplement against cisplatin-induced toxicity in normal renal cells and a combination chemotherapeutic drug with cisplatin in renal cancer cells."
03/01/2012 - "Notably, PGG significantly enhanced cytotoxicity and PARP cleavage in cisplatin-treated Caki-2 renal cancer cells. "
|3.||Brain Injuries (Brain Injury)
11/15/2013 - "Besides, PGG is a well-known antioxidant, and its protective effect against I/R-induced brain injury is thought to be due to its potent antioxidant property. "
11/15/2013 - "Present study was undertaken to evaluate the protective effect of 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (PGG) against transient global ischemia/reperfusion (I/R)-induced brain injury in rats. "
11/15/2013 - "Interestingly, pre-treatment with quercetin (20mg/kg, i.p.), and PGG (5 and 10mg/kg, i.p.) for 7 days showed significant, and dose dependent protection against I/R-induced brain injury by alleviating all the behavioral, neurological, morphological, and histological changes induced by I/R. "
03/01/2010 - "Based on elastase and hyaluronidase inhibitions, and type II collagen expression, it could be suggested that PGG might have an influence on skin conditions when used cosmetically as an active anti-aging ingredient with no cytotoxicity; also, it might be beneficial in relieving painful joint conditions, and thus have relevance for treating arthritis. "
07/01/2014 - "Numerous studies with β-PGG revealed a wide variety of biological activities, such as anti-microbial and anti-cancer functions. "
02/01/2014 - "In the present study we demonstrated that both autophagy and senescence were induced in response to penta-1,2,3,4,6-O-galloyl-β-D-glucose (PGG), a chemopreventive polyphonolic compound, in multiple types of cancer cells. "
09/01/2009 - "For anti-cancer activity, three published in vivo preclinical cancer model studies with PGG support promising efficacy to selectively inhibit malignancy without host toxicity. "
09/01/2009 - "Several in vitro and a handful of in vivo studies have shown that PGG exhibits multiple biological activities which implicate a great potential for PGG in the therapy and prevention of several major diseases including cancer and diabetes. "
10/01/2003 - "Although further studies are needed to elucidate the molecular mechanisms and structure-activity relationship by which PGG exerts its inhibitory actions, our results suggest that PGG might be a candidate for developing anti-inflammatory and cancer chemopreventive agents."
|2.||Collagen Type II (Type II Collagen)
|4.||Pancreatic Elastase (Elastase)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Homologous Transplantation (Allograft)